RxDoctor Payments DataLook up a doctor →

Thomas Privett, MD

Neurology · Lafayette, LANPI 1285632638

Payments from drug & device makers

$14,625in general payments, 2019–2025

Across 745 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Neurocrine Biosciences, Inc.$1K
  • Biogen$997
  • UCB, Inc.$797
  • Lilly USA, LLC$725
  • Teva Pharmaceuticals USA, Inc.$713
  • plus $7K from 35 others

What the payments were for

  • Food & beverage$14,54899%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,625 in reported general payments places this provider in the 75th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$160,268
Medicare patients
549
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm42$33,021
RexultiBrexpiprazole21$29,441
Memantine Hcl1,230$25,502
AptiomEslicarbazepine Acetate15$22,762
GocovriAmantadine Hcl13$22,395
VimpatLacosamide17$18,968
LamictalLamotrigine15$14,868
Ajovy AutoinjectorFremanezumab-Vfrm13$13,720
Ajovy SyringeFremanezumab-Vfrm16$11,801
Nurtec OdtRimegepant Sulfate11$11,694
RytaryCarbidopa/Levodopa11$10,295
KeppraLevetiracetam14$10,087
NuedextaDextromethorphan Hbr/Quinidine11$9,840
Lacosamide150$9,325
Aimovig AutoinjectorErenumab-Aooe11$7,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$171$29,44121 claims
MDD US Operations, LLCGocovri$24$22,39513 claims
UCB, Inc.Vimpat$797$18,96817 claims
PfizerNurtec Odt, Dilantin$550$13,48428 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$395$12,35233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 225 neurology providers in Louisiana.

Other neurology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →